Persons with dispensed medicines; background and generation
Sex | Age | Background and generation | Medicine group (ATC) | Periods | Persons with medicines, relative (%) |
---|---|---|---|---|---|
Total male and female | 0 to 65 years, standardised | Total background and generation | Total | 2020* | 56.54 |
Total male and female | 0 to 65 years, standardised | Total background and generation | A10 Drugs used in diabetes | 2020* | 2.36 |
Total male and female | 0 to 65 years, standardised | Total background and generation | J01 Antibacterials for systemic use | 2020* | 13.90 |
Total male and female | 0 to 65 years, standardised | Total background and generation | N02C Antimigraine preparations | 2020* | 1.38 |
Total male and female | 0 to 65 years, standardised | Total background and generation | N06A Antidepressants | 2020* | 5.03 |
Total male and female | 0 to 65 years, standardised | Total background and generation | R03 Drugs for obstruct. airway diseases | 2020* | 6.70 |
Total male and female | 0 to 65 years, standardised | Dutch background | Total | 2020* | 57.58 |
Total male and female | 0 to 65 years, standardised | Dutch background | A10 Drugs used in diabetes | 2020* | 1.99 |
Total male and female | 0 to 65 years, standardised | Dutch background | J01 Antibacterials for systemic use | 2020* | 14.06 |
Total male and female | 0 to 65 years, standardised | Dutch background | N02C Antimigraine preparations | 2020* | 1.51 |
Total male and female | 0 to 65 years, standardised | Dutch background | N06A Antidepressants | 2020* | 5.23 |
Total male and female | 0 to 65 years, standardised | Dutch background | R03 Drugs for obstruct. airway diseases | 2020* | 6.84 |
Total male and female | 0 to 65 years, standardised | With migration background | Total | 2020* | 54.39 |
Total male and female | 0 to 65 years, standardised | With migration background | A10 Drugs used in diabetes | 2020* | 3.76 |
Total male and female | 0 to 65 years, standardised | With migration background | J01 Antibacterials for systemic use | 2020* | 13.54 |
Total male and female | 0 to 65 years, standardised | With migration background | N02C Antimigraine preparations | 2020* | 1.06 |
Total male and female | 0 to 65 years, standardised | With migration background | N06A Antidepressants | 2020* | 4.63 |
Total male and female | 0 to 65 years, standardised | With migration background | R03 Drugs for obstruct. airway diseases | 2020* | 6.47 |
Total male and female | 0 to 65 years, standardised | 1st generation migration background | Total | 2020* | 47.77 |
Total male and female | 0 to 65 years, standardised | 1st generation migration background | A10 Drugs used in diabetes | 2020* | 4.24 |
Total male and female | 0 to 65 years, standardised | 1st generation migration background | J01 Antibacterials for systemic use | 2020* | 12.08 |
Total male and female | 0 to 65 years, standardised | 1st generation migration background | N02C Antimigraine preparations | 2020* | 0.92 |
Total male and female | 0 to 65 years, standardised | 1st generation migration background | N06A Antidepressants | 2020* | 4.51 |
Total male and female | 0 to 65 years, standardised | 1st generation migration background | R03 Drugs for obstruct. airway diseases | 2020* | 5.11 |
Total male and female | 0 to 65 years, standardised | 2nd generation migration background | Total | 2020* | 59.47 |
Total male and female | 0 to 65 years, standardised | 2nd generation migration background | A10 Drugs used in diabetes | 2020* | 2.43 |
Total male and female | 0 to 65 years, standardised | 2nd generation migration background | J01 Antibacterials for systemic use | 2020* | 14.66 |
Total male and female | 0 to 65 years, standardised | 2nd generation migration background | N02C Antimigraine preparations | 2020* | 1.30 |
Total male and female | 0 to 65 years, standardised | 2nd generation migration background | N06A Antidepressants | 2020* | 4.72 |
Total male and female | 0 to 65 years, standardised | 2nd generation migration background | R03 Drugs for obstruct. airway diseases | 2020* | 7.91 |
Total male and female | 0 to 65 years, standardised | Western migration background | Total | 2020* | 47.03 |
Total male and female | 0 to 65 years, standardised | Western migration background | A10 Drugs used in diabetes | 2020* | 2.01 |
Total male and female | 0 to 65 years, standardised | Western migration background | J01 Antibacterials for systemic use | 2020* | 11.86 |
Total male and female | 0 to 65 years, standardised | Western migration background | N02C Antimigraine preparations | 2020* | 1.03 |
Total male and female | 0 to 65 years, standardised | Western migration background | N06A Antidepressants | 2020* | 4.05 |
Total male and female | 0 to 65 years, standardised | Western migration background | R03 Drugs for obstruct. airway diseases | 2020* | 5.54 |
Total male and female | 0 to 65 years, standardised | Non-western migration background | Total | 2020* | 59.75 |
Total male and female | 0 to 65 years, standardised | Non-western migration background | A10 Drugs used in diabetes | 2020* | 5.35 |
Total male and female | 0 to 65 years, standardised | Non-western migration background | J01 Antibacterials for systemic use | 2020* | 14.80 |
Total male and female | 0 to 65 years, standardised | Non-western migration background | N02C Antimigraine preparations | 2020* | 1.07 |
Total male and female | 0 to 65 years, standardised | Non-western migration background | N06A Antidepressants | 2020* | 5.15 |
Total male and female | 0 to 65 years, standardised | Non-western migration background | R03 Drugs for obstruct. airway diseases | 2020* | 7.13 |
Total male and female | 0 to 65 years, standardised | Morocco | Total | 2020* | 65.33 |
Total male and female | 0 to 65 years, standardised | Morocco | A10 Drugs used in diabetes | 2020* | 7.09 |
Total male and female | 0 to 65 years, standardised | Morocco | J01 Antibacterials for systemic use | 2020* | 16.66 |
Total male and female | 0 to 65 years, standardised | Morocco | N02C Antimigraine preparations | 2020* | 1.19 |
Total male and female | 0 to 65 years, standardised | Morocco | N06A Antidepressants | 2020* | 7.26 |
Total male and female | 0 to 65 years, standardised | Morocco | R03 Drugs for obstruct. airway diseases | 2020* | 8.41 |
Total male and female | 0 to 65 years, standardised | Turkey | Total | 2020* | 65.40 |
Total male and female | 0 to 65 years, standardised | Turkey | A10 Drugs used in diabetes | 2020* | 5.95 |
Total male and female | 0 to 65 years, standardised | Turkey | J01 Antibacterials for systemic use | 2020* | 18.38 |
Total male and female | 0 to 65 years, standardised | Turkey | N02C Antimigraine preparations | 2020* | 1.48 |
Total male and female | 0 to 65 years, standardised | Turkey | N06A Antidepressants | 2020* | 8.64 |
Total male and female | 0 to 65 years, standardised | Turkey | R03 Drugs for obstruct. airway diseases | 2020* | 8.31 |
Total male and female | 0 to 65 years, standardised | Surinam | Total | 2020* | 63.88 |
Total male and female | 0 to 65 years, standardised | Surinam | A10 Drugs used in diabetes | 2020* | 6.15 |
Total male and female | 0 to 65 years, standardised | Surinam | J01 Antibacterials for systemic use | 2020* | 14.20 |
Total male and female | 0 to 65 years, standardised | Surinam | N02C Antimigraine preparations | 2020* | 1.02 |
Total male and female | 0 to 65 years, standardised | Surinam | N06A Antidepressants | 2020* | 3.63 |
Total male and female | 0 to 65 years, standardised | Surinam | R03 Drugs for obstruct. airway diseases | 2020* | 8.70 |
Total male and female | 0 to 65 years, standardised | (former) Net Antilles, Aruba | Total | 2020* | 59.25 |
Total male and female | 0 to 65 years, standardised | (former) Net Antilles, Aruba | A10 Drugs used in diabetes | 2020* | 4.01 |
Total male and female | 0 to 65 years, standardised | (former) Net Antilles, Aruba | J01 Antibacterials for systemic use | 2020* | 14.15 |
Total male and female | 0 to 65 years, standardised | (former) Net Antilles, Aruba | N02C Antimigraine preparations | 2020* | 1.12 |
Total male and female | 0 to 65 years, standardised | (former) Net Antilles, Aruba | N06A Antidepressants | 2020* | 3.22 |
Total male and female | 0 to 65 years, standardised | (former) Net Antilles, Aruba | R03 Drugs for obstruct. airway diseases | 2020* | 8.06 |
Total male and female | 0 to 65 years, standardised | Other non-western background | Total | 2020* | 54.46 |
Total male and female | 0 to 65 years, standardised | Other non-western background | A10 Drugs used in diabetes | 2020* | 4.25 |
Total male and female | 0 to 65 years, standardised | Other non-western background | J01 Antibacterials for systemic use | 2020* | 13.03 |
Total male and female | 0 to 65 years, standardised | Other non-western background | N02C Antimigraine preparations | 2020* | 0.88 |
Total male and female | 0 to 65 years, standardised | Other non-western background | N06A Antidepressants | 2020* | 3.75 |
Total male and female | 0 to 65 years, standardised | Other non-western background | R03 Drugs for obstruct. airway diseases | 2020* | 5.48 |
Source: CBS. |
Table description
This table contains figures on the absolute number of persons to whom in the year concerned medicines were dispensed for which the costs are reimbursed under the statutory basic medical insurance. The figures are also expressed as a percentage of the total population in the category concerned. The population includes everybody registered in the Basic Registration of Persons (BRP) and living in the Netherlands at some point in the year concerned. Until 2010 the figures also included medicines dispensed to persons registered in the BRP, but no longer resident in the Netherlands.
Medicines provided to persons in hospitals and nursing homes are not included; medicines provided in residential homes for the elderly are included.
Data are broken down by medicine group, background, generation, age and sex.
Data available from: 2006
Status of the figures:
Figures for 2020 are provisional. Remaining figures are definite.
Changes as of 10 December, 2021:
Figures for 2019 have been made final and provisional figures for 2020 have been added.
When will new figures be published?
New figures will be published in the last quarter of 2022.
Description topics
- Persons with medicines, relative
- Number of persons to whom medicines are dispensed in the year concerned that are reimbursed under the statutory basic medical insurance, expressed as a percentage of the total population of the category concerned registered in the Basic Registration of Persons (BRP) in that year.